ALENDRONATE SODIUM
Details
- Status
- Prescription
- First Approved
- 2008-02-06
- Routes
- ORAL
- Dosage Forms
- TABLET, SOLUTION
Companies
ALENDRONATE SODIUM Approval History
What ALENDRONATE SODIUM Treats
9 FDA approvalsOriginally approved for its first indication in 2008 . Covers 9 distinct patient populations.
- Other (9)
Other
(9 approvals)- • Approved indication (Feb 2008)Letter
- • Approved indication (Aug 2008)
- • Approved indication (Sep 2008)
- • Approved indication (Apr 2009)
- • Approved indication (Sep 2009)
- • Approved indication (Feb 2010)
- • Approved indication (Feb 2013)
- • Approved indication (May 2023)
- • Approved indication (Jun 2024)
Active Pipeline
Ongoing clinical trials by development phase
Key Completed Trials
Completed studies with published results, ranked by significance
Trial Timeline
Full development history with FDA approval milestones
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
ALENDRONATE SODIUM FDA Label Details
ProIndications & Usage
Alendronate sodium is a bisphosphonate indicated for: Treatment and prevention of osteoporosis in postmenopausal women Treatment to increase bone mass in men with osteoporosis Treatment of glucocorticoid-induced osteoporosis Treatment of Paget's disease of bone Limitations of use: Optimal duration of use has not been determined. For patients at low- risk for fracture, consider drug discontinuation after 3 to 5 years of use. 1.1 Treatment of Osteoporosis in Postmenopausal Women Alendronate sodium tablets, USP are indicated for the treatment of osteoporosis in postmenopausal women. In postmenopa...
Want competitive intelligence?
See who's developing similar drugs and track their progress
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.